"The Gambia Vaccine Trial results are fantastic news for global health. The results extend the findings of previous trials by showing that pneumococcal vaccines protect the world's most vulnerable children - those living in rural Africa - from pneumococcal disease. At PneumoADIP, our work is just beginning as we take on the ambitious goal of assuring access for this vaccine to every child, every where."

Orin Levine,

Executive Director,

GAVI's PneumoADIP

The Gambia study is the first trial in 20 years to show significant reduction in child mortality.

The Gambia study is the first trial in 20 years to show significant reduction in child mortality